Unsolicited AEs within 28 days after any vaccine injections, by system organ class and preferred term (safety analysis set).</p
Neutralizing Antibodies (NAb) determined four weeks after the final vaccination using the TZM-bl cel...
<p>Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...
Subjects reporting solicited injection site reactions after all and each vaccination.</p
<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination ...
Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...
<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vacc...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>Bars represent the maximum severity per volunteers within 28 days after either 2 vaccinations in ...
Frequency of antibody responses as determined by ELISA four weeks after the final vaccination.</p
The time interval required to develop immunity after vaccination, in the event of a bioterrorist att...
Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...
<p>One and two week post vaccination time periods coded as unexposed to account for a delay between ...
The earliest time at which serum antibody levels peak following administration of an influenza virus...
Administered doses by Apr 2, 2021 (end of follow-up time) of each vaccine and number of COVID-19 inf...
<p>None of the preferred term events affected ≥0.1% of the participants; n = number of participants ...
Neutralizing Antibodies (NAb) determined four weeks after the final vaccination using the TZM-bl cel...
<p>Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...
Subjects reporting solicited injection site reactions after all and each vaccination.</p
<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination ...
Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...
<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vacc...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>Bars represent the maximum severity per volunteers within 28 days after either 2 vaccinations in ...
Frequency of antibody responses as determined by ELISA four weeks after the final vaccination.</p
The time interval required to develop immunity after vaccination, in the event of a bioterrorist att...
Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...
<p>One and two week post vaccination time periods coded as unexposed to account for a delay between ...
The earliest time at which serum antibody levels peak following administration of an influenza virus...
Administered doses by Apr 2, 2021 (end of follow-up time) of each vaccine and number of COVID-19 inf...
<p>None of the preferred term events affected ≥0.1% of the participants; n = number of participants ...
Neutralizing Antibodies (NAb) determined four weeks after the final vaccination using the TZM-bl cel...
<p>Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...
Subjects reporting solicited injection site reactions after all and each vaccination.</p